Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: results of the ICTUS-AMI trial.

Zhu TQ, Zhang Q, Ding FH, Qiu JP, Jin HG, Jiang L, Lu L, Zhang RY, Hu J, Yang ZK, Shen Y, Shen WF.

Chin Med J (Engl). 2013 Aug;126(16):3079-86.

PMID:
23981616
2.

Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.

Zhu TQ, Zhang Q, Qiu JP, Jin HG, Lu L, Shen J, Zhao LP, Zhang RY, Hu J, Yang ZK, Shen WF.

Int J Cardiol. 2013 May 25;165(3):437-43. doi: 10.1016/j.ijcard.2011.08.082. Epub 2011 Sep 21.

PMID:
21940058
3.
4.

Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.

Coron Artery Dis. 2008 Jun;19(4):271-7. doi: 10.1097/MCA.0b013e3282f487e0.

PMID:
18480672
5.

Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Kırma C, Erkol A, Pala S, Oduncu V, Dündar C, İzgi A, Tigen K, Gibson CM.

Catheter Cardiovasc Interv. 2012 Jan 1;79(1):59-67. doi: 10.1002/ccd.23109. Epub 2011 Nov 30.

PMID:
21523892
6.

[Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].

Yang XC, Zhang DP, Wang LF, Xu L, Ge YG, Wang HS, Li WM, Ni ZH, Xia K, Lian Y, Xue YL, Ma LX.

Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jun;35(6):517-22. Chinese.

PMID:
17711710
7.
9.
10.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

11.

Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).

Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A; FATA Trial Investigators.

Am J Cardiol. 2009 Mar 15;103(6):785-90. doi: 10.1016/j.amjcard.2008.11.029. Epub 2009 Jan 21.

PMID:
19268732
12.

Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.

Yan HB, Li SY, Song L, Wang J, Wu Z, Chi YP, Zheng B, Zhao HJ, Li QX, Zhang XJ, Li WZ.

Chin Med J (Engl). 2010 Apr 5;123(7):877-83.

PMID:
20497681
13.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

14.
15.

Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.

Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W.

Chin Med J (Engl). 2008 Mar 20;121(6):522-7.

PMID:
18364139
16.

Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.

Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, Stone GW.

Circ Cardiovasc Interv. 2013 Jun;6(3):216-23. doi: 10.1161/CIRCINTERVENTIONS.112.000142. Epub 2013 May 7.

18.

Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction).

Niccoli G, Rigattieri S, De Vita MR, Valgimigli M, Corvo P, Fabbiocchi F, Romagnoli E, De Caterina AR, La Torre G, Lo Schiavo P, Tarantino F, Ferrari R, Tomai F, Olivares P, Cosentino N, D'Amario D, Leone AM, Porto I, Burzotta F, Trani C, Crea F.

JACC Cardiovasc Interv. 2013 Jun;6(6):580-9. doi: 10.1016/j.jcin.2013.02.009. Epub 2013 May 15.

19.
20.

Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Wang K, Zuo G, Zheng L, Zhang C, Wang D, Cao Z, Hu S, Du X.

Cell Biochem Biophys. 2015 Jan;71(1):135-42. doi: 10.1007/s12013-014-0173-4.

PMID:
25123839

Supplemental Content

Support Center